Abstract
Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.
Keywords: Combined therapies, enzyme replacement therapy, gene therapy, hematopoietic cell transplantation, lysosomal storage diseases, small molecular chaperones, substrate reduction therapy.
Current Molecular Medicine
Title:Combined Therapies for Lysosomal Storage Diseases
Volume: 15 Issue: 8
Author(s): M. Gabig-Cimińska, J. Jakóbkiewicz-Banecka, M. Malinowska, A. Kloska, E. Piotrowska, I. Chmielarz, M. Moskot, A. Węgrzyn and G. Węgrzyn
Affiliation:
- Department of Molecular Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland.,Poland
Keywords: Combined therapies, enzyme replacement therapy, gene therapy, hematopoietic cell transplantation, lysosomal storage diseases, small molecular chaperones, substrate reduction therapy.
Abstract: Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.
Export Options
About this article
Cite this article as:
Gabig-Cimińska M., Jakóbkiewicz-Banecka J., Malinowska M., Kloska A., Piotrowska E., Chmielarz I., Moskot M., Węgrzyn A. and Węgrzyn G., Combined Therapies for Lysosomal Storage Diseases, Current Molecular Medicine 2015; 15(8) . https://dx.doi.org/10.2174/1566524015666150921105658
DOI https://dx.doi.org/10.2174/1566524015666150921105658 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design Bronchial Thermoplasty: Burn to Cure?
Current Respiratory Medicine Reviews Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Inhaled Hypertonic Saline as a Therapeutic Strategy to Dampen Inflammation in Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Diabetic Patients with Psychiatric Illness
Current Diabetes Reviews HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Physical Delivery Enhancement of Topical Drugs
Current Pharmaceutical Design Candida Infections and Human Defensins
Protein & Peptide Letters Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications
Current Pharmaceutical Biotechnology